Mereo BioPharma (MREO) Enterprise Value (2017 - 2026)

Mereo BioPharma (MREO) has reported Enterprise Value for 10 consecutive years, with -$36.2 million the latest figure, recorded in Q1 2026.

• Quarterly Enterprise Value rose 42.04% year-over-year to -$36.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.2 million (up 42.04% YoY) and the FY2025 annual result came in at -$41.0 million, up 41.27% from the prior year.
• Enterprise Value rose to -$36.2 million in Q1 2026 per MREO's latest filing, from -$41.0 million in the prior quarter.
• Over the last five years, Enterprise Value for MREO reached as high as -$36.2 million in Q1 2026 and fell as low as -$96.2 million in Q2 2022.
• A 5-year average of -$61.8 million and a median of -$57.4 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value surged 48.02% — and 2024, when it plunged 65.91%.
• Year by year, Enterprise Value stood at -$66.1 million in 2022, then climbed by 13.1% to -$57.4 million in 2023, then slipped by 21.56% to -$69.8 million in 2024, then surged by 41.27% to -$41.0 million in 2025, then rose by 11.63% to -$36.2 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$36.2 million, -$41.0 million, and -$48.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.